PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma

Infectious Agents and Cancer

Yi Cui¹  Jinhua Hu¹  Lei Wu¹  Xiangguo Tian¹  Tao Li¹  Juan Liu¹  Jingfang Zhao¹  Yuanzi Yu¹  Shengqing Gu²  Meng Kong³  Shaocan Tang⁴ 

[1] Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University;Department of Gastroenterology, Shouguang peoples’ Hospital;Department of Gastrointestinal surgery, Provincial Hospital affiliated to Shandong University;Department of rehabilitation, Provincial Hospital affiliated to Shandong University;

关键词: Hepatocellular carcinoma;    PIVKA-II;    Portal vein tumor thrombus;   

DOI  :  10.1186/s13027-019-0229-6

来源: DOAJ

【 摘 要 】

Abstract Aim To evaluate the correlation of serum PIVKA-II levels and development of portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients. Methods One hundred and twenty-three patients with newly diagnosed HCC were included in this study between March 2016 and October 2018. Thirty-five of these patients were detected with PVTT and all subjects were randomly divided to analysis group (N = 73) and validation (N = 50) group. Serum levels of PIVKA-II, laboratory tests including serum aspartate aminotransferase, total bilirubin, platelet count, albumin levels were demonstrated in all the patients. T-test, chi-squared test and logistic regression was used for analyzing data. Diagnostic efficiency and cut-off value of PIVKA-II in PVTT development of HCC patients were calculated using receiver operator curve (ROC) analysis. Results Serum level of PIVKA-II in HCC patients with PVTT was significantly higher than that in HCC patients without PVTT (995.8 mAU/ml vs 94.87 mAU/ml; P = 0.003), as well as D-dimer levels (2.12 mg/L vs 0.56 mg/L P = 0.001). Univariate analysis showed that high serum D-dimer level was an independent risk factor for development of PVTT (OR = 1.22, 95%CI 1.02–1.45). ROC curve showed that among analysis group, the area under ROC curve (AUROC) of PIVKA-II was 0.73 (95%CI 0.59–0.86). For the detection of PVTT in HCC, PIVKA-II had a sensitivity of 83.7% and a specificity of 69.2% at a cutoff of 221.26 mAU/ml, which had a sensitivity of 85.71% and a specificity of 55.56% in validation group, respectively. Conclusion Serum PIVKA-II level is a potential marker for diagnosis of PVTT in HCC patients, which may guide therapeutic strategy and assessment of tumor prognosis of HCC.

【 授权许可】

Unknown